ArticleCase reports in oncology

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab.

Tatiana Strava Corrêa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.